Responses
Clinical/translational cancer immunotherapy
Original research
Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence
Compose a Response to This Article
Other responses
No responses have been published for this article.